Systematic review reports treatment challenges with EGFR-focused TKIs in glioblastoma, highlighting implications for future therapies.
EGFR-focused TKIs were largely disappointing as a treatment for GBM. Longstanding issues, including treatment resistance, tumor heterogeneity, and blood-brain barrier penetration persist. Future efforts must focus on tackling these issues, and prioritizing patient selection via biomarkers.
No takes yet. Share an insight, caveat, or question.
Berro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: